Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesGenetic & Molecular TestingBlue Cross Blue Shield RI Genetic Testing Prior Au…
    Ask Trek AI about this page
    DraftBlue Cross Blue Shield - Rhode IslandPolicy N/A

    Genetic Testing Services

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts

    Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity, prior authorization, and coverage stance for genetic and molecular testing services for BCBSRI Medicare Advantage and Commercial products, including panel testing and multianalyte assays.

    Policy Summary
    PayerBlue Cross Blue Shield - Rhode Island
    PolicyGenetic Testing Services
    Policy CodePolicy N/A
    Change TypeRoutine review — no material changes
    Effective Date06/01/2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests via the BCBSRI online prior authorization tool (fax only for non‑participating providers); prior authorization required for Medicare Advantage and recommended for Commercial products.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    MA requiredauthorization requirement
    Commercial recommendedrecommended authorization
    PCP exemption 10/01/2025PCP exemption
    06/01/2026policy effective date

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    1
    external coding grid
    7named categories

    Coverage Criteria

    General genetic testing medical necessity

    Genetic screening or testing is considered medically necessary when the diagnostic test of the individual's germline will benefit the individual and one of the following is met.

    Indications: To confirm a suspected diagnosis in a patient with signs and/or symptoms of the condition; OR to identify a causative etiology for a clinical syndrome with multiple possible underlying conditions; OR testing an asymptomatic individual to determine future risk of disease.

    General germline testing criteria from policy; used by online authorization tool.

    Carrier screening (preconception or prenatal)

    Covered when ALL of the following are met:

    Carrier screening criteria: One or both individuals have a first- or second-degree relative who is affected; OR one individual is a known carrier; OR one or both individuals are members of a population with a carrier rate that exceeds a threshold considered appropriate for testing for that condition; AND previous carrier screening or individual targeted gene testing for the variant(s) of interest has not been performed.population carrier rate exceeds appropriate threshold

    First- and second-degree relatives defined in policy.

    Genetic testing for cancer

    Considered medically necessary when any of the following are met:

    Cancer testing indications: Testing an asymptomatic patient to determine future risk of cancer; OR therapeutic testing of cancer cells from an affected individual to direct targeted treatment based on specific somatic variants.

    Includes both germline cancer risk assessment and somatic tumor profiling to guide therapy.

    Medical Necessity Requirement

    Covered when clinical utility and clinical validity are demonstrated; conversely tests with insufficient evidence are not covered.

    General coverage logic: Tests must have demonstrated clinical utility and sufficient evidence of clinical validity to be considered medically necessary. Tests lacking sufficient clinical evidence, or for which results would not reasonably be used in patient management or would not impact therapeutic decision‑making, are considered not medically necessary and not covered.clinical utility/validity demonstrated

    Per‑test coverage and code‑level determinations are provided in the referenced coding spreadsheet effective 6/1/2026.

    Genetic testing services are not covered for Medicare Advantage Plans and are considered not medically necessary for Commercial Products when any of the following apply: there is insufficient clinical evidence or strength of recommendation; test results would not reasonably be used in the management of the patient; or the service is unlikely to impact therapeutic decision-making in the clinical care of the member. Some services may also be excluded for specific self‑funded groups per their benefit booklets and the state Biomarker Testing Mandate exceptions — refer to the Coding section and the applicable Benefit Booklet for plan‑specific coverage.

    Laboratories and third parties are not permitted to obtain prior authorization or otherwise participate on behalf of the ordering physician; only the ordering physician may complete authorization, appeals, or related administrative processes. Services provided without required authorization may be denied and assessed as the financial responsibility of the providing laboratory or entity.

    Tests for which there is insufficient published data or an insufficient evidence base demonstrating clinical validity are considered not medically necessary. When available evidence does not establish that the test reliably identifies a clinically meaningful variant or that the result will inform management to improve health outcomes, the test will not be covered.

    Entire genetic panel tests are considered not covered for Medicare Advantage Plans and not medically necessary for Commercial Products when there is insufficient evidence that the panel as composed leads to improved health outcomes, or when one or more genes/variants in the panel lack evidence of clinical utility. For panel tests represented by individual CPT codes, coverage determinations are made per the attached code grid and the PLA/MAAA policy as applicable.

    The policy identifies that several tests lack demonstrated clinical utility due to extremely limited published data or insufficient evidence of clinical validity; such tests are considered not medically necessary. Where evidence is inadequate to determine effects on health outcomes, the tests are excluded from coverage.

    Covered Indications

    Diagnostic confirmation, etiologic diagnosis, asymptomatic risk assessment, cancer risk assessment, somatic tumor profiling to direct targeted therapy

    Genetic testing is covered for the following clinical indications when the general medical necessity requirements are met:

    Covered indications: Diagnostic confirmation of a suspected genetic condition in a symptomatic individual; OR etiologic genetic diagnosis to identify the cause of a clinical syndrome with multiple possible underlying conditions; OR asymptomatic germline testing to assess future risk of a hereditary disease; OR cancer-related testing: (a) germline testing to determine inherited cancer risk in an asymptomatic individual, or (b) somatic tumor profiling of cancer cells from an affected individual to identify variants that direct targeted therapy.

    Apply prior authorization and per‑test criteria from the online tool and attached code grid as applicable.

    Genetic tests with demonstrated clinical utility and validity for specified indications as listed in external coding & coverage spreadsheet

    Coverage for specific genetic tests and codes is determined by demonstrated clinical utility and validity and is listed in the external coding and coverage spreadsheet.

    Coding‑linked coverage:

    Eligibility Requirements

    Eligibility for genetic testing requires that the test be expected to benefit the individual and meet the applicable medical‑necessity criteria in the online authorization tool or this policy (for example, diagnostic confirmation, etiologic diagnosis of a clinical syndrome, asymptomatic risk assessment, or cancer‑related indications). Specific eligibility nodes and per‑test requirements are implemented in the authorization tool and external coding grid referenced in this policy.

    For carrier screening (preconception or prenatal), coverage requires that one or more of the following be present: a first‑ or second‑degree relative affected by the condition, one individual known to be a carrier, or membership in a population with an elevated carrier rate; additionally, previous carrier screening or targeted testing for the variant(s) of interest must not have been performed. Other eligibility elements (family history, prior testing, and indication‑specific criteria) are implemented through the online authorization criteria sets and the attached coding spreadsheet.

    Coding

    Referenced code categoriesmixed
    PLA/MAAAProprietary Laboratory Analyses and Multianalyte Assays with Algorithmic Analyses referenced; see separate PLA/MAAA Policy
    Genetic Testing Codes (referenced external grid)mixed
    See attached spreadsheetGenetic Testing Codes and Coverage Effective 6/1/2026 (external XLSX referenced)
    Carrier screening population carrier rate — threshold for testing
    Population carrier rate thresholdTesting is indicated when one or both individuals are members of a population known to have a carrier rate that exceeds a threshold considered appropriate for testing for a particular condition.
    Context of useApplies to preconception or prenatal carrier screening as part of medical necessity criteria.
    Additional requirementPrevious carrier screening or targeted testing for the variant(s) of interest must not have been performed.

    Provider Actions & Requirements

    Prior Authorization

    Prior authorization required for MA; recommended for Commercial (see attached spreadsheet)

    For those tests indicated in the attached code grid, prior authorization is required for Medicare Advantage Plans and recommended for Commercial Products; for Fully-Funded Commercial Products only, contracted BCBSRI primary care providers may be exempt effective 10/1/2025. See the attached external coding spreadsheet for per-test determinations.

    • Prior authorization required for Medicare Advantage when indicated in the attached code grid.
    • Prior authorization recommended for Commercial Products when indicated in the attached code grid.
    • Exemption: Effective 10/1/2025, contracted PCPs for Fully-Funded Commercial Products may not need prior authorization.
    Prior Authorization

    Authorization and coverage tied to external code grid (see attached spreadsheet)

    Coverage and prior authorization requirements are tied to an external coding grid: the attached spreadsheet specifies which genetic testing codes may be covered, medically necessary if criteria are met, not medically necessary, or not covered for Medicare Advantage and Commercial products effective 6/1/2026.

    Not Covered / Not Medically Necessary

    Panels or tests that lack sufficient evidence of clinical utility are not covered for Medicare Advantage and are considered not medically necessary for Commercial Products. When a panel cannot be shown to improve net health outcomes, the entire panel is excluded; per‑code determinations for panels filed with specific CPT codes are available in the policy's coding grid and the PLA/MAAA policy.

    Tests that do not demonstrate clinical utility or lack sufficient evidence of clinical validity are explicitly considered not covered (Medicare Advantage) or not medically necessary (Commercial Products). The policy states that when evidence is inadequate to determine the impact on health outcomes, coverage is denied.

    Background

    Molecular pathology and genomic sequencing procedures analyze DNA and RNA to detect germline or somatic variants and to guide testing selection based on specific genes or regions. Next‑generation sequencing‑based panels, exome, genome, and other multianalyte assays may assay multiple genes or regions and panel composition varies by laboratory; clinical validity and clinical utility are condition‑specific. The policy notes limitations of genetic testing including possible failure to detect all variants, identification of variants of uncertain significance, genetic and phenotypic heterogeneity, and potential laboratory error, all of which affect interpretation and clinical application.

    Definitions

    Genetic Testing — definition
    DefinitionAnalysis of chromosomes, DNA, RNA, genes, or gene products to detect inherited (germline) or noninherited (somatic) genetic variants related to disease or health.
    ScopeIncludes testing to detect variants in chromosomes, nucleotide sequences, and gene products for diagnostic, predictive, or therapeutic purposes.
    Variants detectedCovers both germline (inherited) and somatic (acquired) variants.
    Carrier Testing — definition and populations
    Who should be offeredPeople with family members who have a genetic condition; individuals with family members who are identified carriers; and members of ethnic or racial groups with higher carrier rates for a particular condition.
    Clinical contextUsed for preconception or prenatal screening and when one individual is a known carrier or a first- or second-degree relative is affected.
    Policy Summary
    PayerBlue Cross Blue Shield - Rhode Island
    PolicyGenetic Testing Services
    Policy CodePolicy N/A
    Change TypeRoutine review — no material changes
    Effective Date06/01/2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests via the BCBSRI online prior authorization tool (fax only for non‑participating providers); prior authorization required for Medicare Advantage and recommended for Commercial products.
    SourceLink
    On This Page
    Coverage CriteriaCovered IndicationsEligibility RequirementsCodingProvider Actions & RequirementsNot Covered / Not Medically NecessaryBackgroundDefinitions
    Per‑test indications and coverage determinations are specified in the attached Genetic Testing Codes and Coverage spreadsheet (effective 6/1/2026); coverage for a given CPT/PLA/MAAA code is contingent on meeting the listed clinical indications and evidence requirements.
    demonstrated clinical utility and validity per spreadsheet

    See attached grid for which codes may be covered, medically necessary if criteria are met, not medically necessary, or not covered.

    • Refer to the external spreadsheet (Genetic Testing Codes and Coverage Effective 6/1/2026) for code-level coverage and authorization requirements.
    • Some tests' medical necessity is determined by the diagnosis code submitted with the claim per the attached grid.
    Note

    Provider must follow authorization and documentation processes as specified

    Ordering providers must follow the policy's authorization and documentation processes exactly as stated; any additional or alternative administrative requirements are not specified in this segment.

    Step Therapy

    Step therapy: none specified

    No step therapy requirements are specified in this portion of the policy.

    Billing Rule

    Submit authorizations via BCBSRI online tool; panels require per‑CPT entry

    Submit authorization requests using the BCBSRI online prior authorization tool (available to BCBSRI-participating providers); providers not in the online tool must fax requests to Utilization Management at (401) 272-8885. For panel testing represented by multiple CPT codes, prior authorization is required for each component/CPT code and must be entered and processed independently.

    • Use BCBSRI online prior authorization tool when available to the provider.
    • Fax prior authorization requests to Utilization Management at (401) 272-8885 if the provider cannot use the online tool or the test is not found online.
    • For panels represented by multiple CPT codes, submit prior authorization for each individual CPT code separately.
    Documentation Required

    Verify member benefits and obtain consent before billing for non‑covered services

    Verify member benefits and eligibility prior to testing. Do not charge members for services determined not medically necessary unless the member has been informed and provided written agreement to pay out-of-pocket in advance.

    • Confirm member-specific benefits and eligibility via provider call center or member documents.
    • Obtain written informed agreement before billing a member for services that are not medically necessary.
    Denial Risk

    Labs/third parties may not obtain or facilitate authorization or appeals

    Laboratories and third parties are prohibited from obtaining or facilitating prior authorization or appeals on behalf of the ordering physician; if a laboratory or third party supports any portion of the authorization process, BCBSRI will deem it a violation and may take severe action, and services provided without authorization will be denied as the laboratory's financial liability.

    • Only the ordering physician shall be involved in authorization, appeal, or other administrative processes related to prior authorization/medical necessity.
    • If a laboratory provides a service that has not been authorized, the service will be denied and billed as the financial liability of the participating laboratory.
    Denial Risk

    Insufficient evidence (clinical utility/validity) may lead to denial

    Tests that lack demonstrated clinical utility or have insufficient evidence of clinical validity are considered not medically necessary and may be denied.

    • Entire genetic panel tests may be not covered when there is insufficient evidence that the panel improves health outcomes.
    • Tests with extremely limited published data or insufficient evidence of clinical validity are considered not medically necessary.
    Documentation Required

    Ordering physician must submit authorizations and follow code‑level guidance

    Ensure the ordering physician submits any required prior authorization and follows policy requirements; follow the external code grid and online tool instructions for documentation and code entry.

    • Ordering physician is responsible for submitting prior authorization requests.
    • Follow the external coding grid for per-test requirements and claim coding guidance.
    Prior Authorization

    Ordering physician must submit prior authorization; PCP exemption for contracted PCPs (10/1/2025)

    The ordering physician must submit prior authorization requests; for Fully-Funded Commercial Products only (effective 10/1/2025), contracted BCBSRI primary care providers in listed specialties may be exempt from prior authorization requirements for certain tests.

    • Ordering physician is responsible for prior authorization submission.
    • PCP exemption (effective 10/1/2025) applies to credentialed specialties listed in the policy for Fully-Funded Commercial Products only.
    Carrier statusA carrier typically has one abnormal allele for a disorder and may be unaffected for autosomal recessive or X-linked disorders.
    Germline Variants — definition
    DefinitionVariants present in the DNA of every cell of the body from the moment of conception; include cells in the gonads and therefore may be passed on to offspring.
    Transmission riskBecause germline variants include gonadal cells (testes or ova), they can be transmitted to offspring.
    Clinical relevanceGermline testing assesses inherited risk and can inform diagnosis, family counseling, and reproductive decision-making.
    Somatic Variants — definition
    DefinitionVariants that arise with the passage of time and are restricted to a specific cell or cells derived from it; if not present in gonadal cells, they are not passed to offspring.
    OccurrenceTypically represent acquired changes in somatic tissues (eg, tumors) rather than inherited alterations.
    Clinical useSomatic variant detection is commonly used for tumor profiling to guide targeted therapy.
    Germline Variants — (alternate placement)
    ImplicationRelevant for inherited disease risk and reproductive counseling.
    DetectionIdentified through germline genetic testing of blood or saliva samples.
    Somatic Variants — (alternate placement)
    Definition (alternate placement)Somatic variants occur over time, are restricted to specific cell(s), and are not passed to offspring if not present in gonadal cells.
    Typical samplesDetected in affected tissue (eg, tumor biopsies) rather than germline samples.
    Use casePrimarily used to direct targeted cancer therapies and assess tumor biology.
    Pharmacogenomics — definition
    DefinitionPharmacogenomics studies how a person’s genetic makeup affects his or her body’s response to drugs.
    PurposeUsed to predict drug efficacy, risk of adverse reactions, and to guide medication selection or dosing.
    Test typesMay involve testing of germline variants that influence drug metabolism, transport, or targets.